Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Nancy G. Azizian"'
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Chemotherapy resistance poses a major obstacle in cancer therapy. Here, the authors identify the mTOR pathway as a determinant of chemosensitivity and demonstrate that inhibition of mTOR promotes the persistence of a chemotherapy-resistant cancer-cel
Externí odkaz:
https://doaj.org/article/48df2d8aba604f5392daade1ac614d9d
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers, is driven by oncogenic KRAS mutations. Farnesyl thiosalicylic acid (FTS), also known as salirasib, is a RAS inhibitor that selectively dislodges active RAS p
Externí odkaz:
https://doaj.org/article/6e4cb1857d5a4b5b94e7d6deb5c10700
Autor:
Nancy G. Azizian, Yulin Li
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-9 (2020)
Abstract Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and mult
Externí odkaz:
https://doaj.org/article/b0951e579f2c4d29af7ea8e901dae569
Publikováno v:
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-8 (2019)
Abstract Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2, and/or BCL6 oncogenes. Due to the simultaneous overexpression of these driver oncogenes, DHLs are hig
Externí odkaz:
https://doaj.org/article/b7bf181559894bbbbd274113d447e1a9
Chemotherapy can eradicate a majority of cancer cells. However, a small population of tumor cells often survives drug treatments through genetic and/or non-genetic mechanisms, leading to tumor recurrence. Here we report a reversible chemoresistance p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13fd7511bbd564aaf03738e2ae5bd5b5
https://doi.org/10.1101/2022.01.19.476916
https://doi.org/10.1101/2022.01.19.476916
Autor:
Susan T. Weintraub, Junjie Chen, Dana Molleur, Delaney K. Sullivan, Sammy Pardo, Nancy G. Azizian, Litong Nie, Yulin Li
Publikováno v:
J Proteome Res
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers. Dissecting the tumor cell proteome from that of the non-tumor cells in the PDAC tumor bulk is critical for tumorigenesis studies, biomarker discovery, and development of therapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c2910b0fb202ed157ad542decedc487
https://pubmed.ncbi.nlm.nih.gov/33289385
https://pubmed.ncbi.nlm.nih.gov/33289385
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Background Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers, is driven by oncogenic KRAS mutations. Farnesyl thiosalicylic acid (FTS), also known as salirasib, is a RAS inhibitor that selectively dislodges active RAS proteins f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649a0475080d9004240a5d62a2f2478d
https://pubmed.ncbi.nlm.nih.gov/33676427
https://pubmed.ncbi.nlm.nih.gov/33676427
Autor:
Nancy G. Azizian, Delaney K. Sullivan, Sammy Pardo, Dana Molleur, Yulin Li, Junjie Chen, Litong Nie, Susan T. Weintraub
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers. Dissecting the tumor cell proteome from that of the non-tumor cells in the PDAC tumor bulk is critical for tumorigenesis studies, biomarker discovery, and development of therapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1be995548da44282a2648b6bca00736a
https://doi.org/10.1101/2020.05.25.113670
https://doi.org/10.1101/2020.05.25.113670
Publikováno v:
International Journal of Hematologic Oncology
“Double-hit lymphomas with MYC and BCL2 translocations can be effectively treated by combined targeting of the driver oncogenes”.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd9654b77084d13bdee2ee985ef25fbb
https://pubmed.ncbi.nlm.nih.gov/31850145
https://pubmed.ncbi.nlm.nih.gov/31850145
Autor:
Azizian, Nancy G.1,2 (AUTHOR), Li, Yulin1,2 (AUTHOR) yli@houstonmethodist.org
Publikováno v:
Journal of Hematology & Oncology. 6/1/2020, Vol. 13 Issue 1, p1-9. 9p.